Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Immunocore Holdings (IMCR) over the last 3 years, with Q3 2025 value amounting to $15.1 million.

  • Immunocore Holdings' Change in Accured Expenses fell 4331.57% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.7 million, marking a year-over-year decrease of 5863.46%. This contributed to the annual value of $71.5 million for FY2024, which is 8292.57% up from last year.
  • Immunocore Holdings' Change in Accured Expenses amounted to $15.1 million in Q3 2025, which was down 4331.57% from $33.7 million recorded in Q2 2025.
  • Immunocore Holdings' Change in Accured Expenses' 5-year high stood at $33.7 million during Q2 2025, with a 5-year trough of -$10.9 million in Q1 2025.
  • Moreover, its 3-year median value for Change in Accured Expenses was $15.1 million (2025), whereas its average is $13.5 million.
  • Per our database at Business Quant, Immunocore Holdings' Change in Accured Expenses surged by 31881.14% in 2024 and then plummeted by 15708.7% in 2025.
  • Immunocore Holdings' Change in Accured Expenses (Quarter) stood at $16.0 million in 2023, then plummeted by 107.67% to -$1.2 million in 2024, then skyrocketed by 1334.34% to $15.1 million in 2025.
  • Its Change in Accured Expenses was $15.1 million in Q3 2025, compared to $33.7 million in Q2 2025 and -$10.9 million in Q1 2025.